Cannibal robot? Scientists develop a robot that can grow and heal by eating others
Researchers from Columbia University in the United States have developed a robot, called the Truss Link, that can detect and merge with pieces of robots nearby to fill in missing parts.
"True autonomy means robots must not only think for themselves but also physically sustain themselves," Philippe Martin Wyder, lead author and researcher at Columbia Engineering and the University of Washington, wrote in a statement.
Related
China unveils tiny spy drone that looks like a mosquito. What other small spy drones exist?
Made with magnetic sticks, the Truss Link can expand or transform from a flat shape to a 3D structure to adapt to the environment.
It can also add new bits from other robots or discard old parts that are not functional anymore to increase its performance.
In a video posted by the team, the robot merges with a piece nearby and uses it as a walking stick to increase its speed by more than 50 per cent.
Related
This new artificial muscle can move just like human muscles but it's 17 times stronger
'Gives legs to AI'
Researchers named the process in which the robot self-assembles bits of other robots 'robot metabolism'. It is described as a natural biological organism that can often absorb and integrate resources.
Robots like the Truss Link can 'provide a digital interface to the physical world, and give legs to AI,' according to a video produced by Columbia Engineering School.
Integrated with AI, they possess great potential, experts believe.
"Robot metabolism provides a digital interface to the physical world and allows AI to not only advance cognitively, but physically – creating an entirely new dimension of autonomy," said Wyder.
The Truss Link could, in future, be used to help develop groundbreaking technologies spanning from marine research to rescue services to extraterrestrial life.
Related
Stanford engineers have taken a leaf out of nature's book to build this bird robot
"Ultimately, it opens up the potential for a world where AI can build physical structures or robots just as it, today, writes or rearranges the words in your email," Wyder said.
Programming robots has been a challenge for engineers; however, artificial intelligence is advancing developments in robotics.
'We now have the technology [AI] to make robots really programmable in a general-purpose way and make it so that normal people can programme them, not just specific robot programming engineers," Rev Lebaredian, vice president of Omniverse and simulation technology at Nvidia, told Euronews Next in May.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Interactive Brokers considers launching new stablecoin for customers
By Anirban Sen NEW YORK (Reuters) -Interactive Brokers Group is considering launching a stablecoin for customers, joining a number of large financial firms that are betting big on the digital token boom as the U.S. eases regulations around the crypto industry. The deliberations come at a time when the underlying infrastructure of global financial markets is undergoing a once-in-a-generation transformation due to the proliferation of blockchain-based assets like stablecoins. In an interview with Reuters, Interactive Brokers' billionaire founder Thomas Peterffy said the company is working on potentially issuing stablecoins, but has yet to make a final decision on how that will be offered to customers. Interactive Brokers, which is one of the world's leading discount brokers with a market value of about $110 billion, currently has a partnership with crypto platform Paxos and is also an investor in crypto exchange Zero Hash. Through these tie-ups, Interactive Brokers offers trading in various cryptocurrencies to customers. The popular trading platform is now working on enabling instant, 24/7 stablecoin funding for brokerage accounts, as well as supporting asset transfers for commonly traded cryptocurrencies, said Peterffy, who also sounded a note of caution on the risks of rapid widespread adoption of crypto. "It's basically hard to grasp its fundamental value. If we see people adopting it and ascribing a value to it, I'm okay with that, but I'm still not convinced," said Peterffy. Among the options being considered, the Greenwich, Connecticut-based firm could allow customers to use stablecoins issued by other financial institutions to fund their accounts, depending upon the credibility of the issuer. Stablecoins are blockchain-based tokens acting as a proxy for an asset that allow people to move money across borders without interacting with the banking system. Critics have warned that this makes them useful for criminals who want to avoid banks' anti-money laundering checks. Online brokerage firm Robinhood recently launched a stablecoin pegged to the U.S. dollar called the Global Dollar Network through a consortium that included other crypto platforms like Kraken and Galaxy Digital. The Global Dollar Network is based around a stablecoin called USDG, which is issued by Paxos. Interactive Brokers, which last year launched a predictions market called ForecastEx that allows investors to buy "yes" or "no" contracts in response to questions, is one of the largest U.S. trading platforms with about 3.87 million customer accounts at the end of June, a jump of 32% from last year. Like other brokerages, Interactive Brokers has benefited from elevated levels of trading due to market volatility this year that was triggered by U.S. tariff policy. Its shares have surged about 47% since the start of the year, outperforming the S&P 500 Investment Banking & Brokerage index, which has risen roughly 20% during the same period. "We view the two innovations (prediction markets and crypto investments) as an effective hedge to any disruption in the firm's core equity, futures, and derivatives businesses," Morningstar analysts said in a note dated July 18. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
AccessFintech Appoints Sarah Shenton Chief Executive Officer
Longtime board member and capital markets leader to guide company's next phase of product innovation and global growth NEW YORK, July 28, 2025 /PRNewswire/ -- AccessFintech, the data network driving capital optimization and greater operational capacity, today announced the appointment of Sarah Shenton as Chief Executive Officer, effective immediately. This strategic leadership change marks a significant step for the company as it positions itself for its next phase of growth. Shenton brings over 20 years of experience in operations, engineering and strategic investing to AccessFintech. Most recently, she led the Value Accelerator at Goldman Sachs' alternative assets business, where she collaborated with leadership teams at high-growth companies to drive scale, operational efficiency and commercial success. A long-time advocate for AccessFintech, Shenton led Goldman Sachs' Series A investment in the company and served as a Board Director from 2018 to 2025. She succeeds John Shay, who has effectively led the company as Interim CEO. John will remain part of the firm as Special Advisor to the CEO, ensuring a seamless transition and offering continued support and industry expertise to the leadership team. "Sarah brings a rare combination of operational depth, technical insight and strategic vision to the CEO role," said John Shay. "Her deep knowledge of our company and industry, alongside her commitment to our mission, will be invaluable as we embark on our next growth phase." "I am honored to take on the role of CEO," said Sarah Shenton. "We've created a strong foundation and an ecosystem that matters, and now is the time to build on this success and deliver exceptional value to clients. As technology continues to transform markets, I look forward to working with our amazing team to seize the exciting opportunities ahead." Shenton's appointment follows a unanimous decision by the Board, built on years of close collaboration during her tenure as a Director since 2018. "Sarah's deep market expertise and long-standing commitment to AccessFintech's vision make her exceptionally well-suited to guide the organization into its next chapter of growth," said Kevin Marcus, Partner at WestCap, on behalf of the AccessFintech Board. "We are also deeply grateful to John Shay for his steady leadership as Interim CEO and are pleased he will continue to play an active role on the team as an Advisor." AccessFintech has built a powerful data and workflow platform —the Synergy Network— that connects and distributes 75+ distinct data sets across 250+ leading financial institutions, enabling real-time collaboration and execution management across the post-trade lifecycle. Under Shenton's leadership, the company will continue to strengthen its role as a critical player in capital markets infrastructure and advance its mission to improve financial operations for clients. About AccessFintechAccessFintech enables improved data sharing and workflow collaboration to evolve the financial industry's operating model. At its core is the AccessFintech Synergy Network, a modern and secure collaboration network that allows for resolution and decision-making in one place. It facilitates data collaboration at scale and provides more visibility into transaction data and access to benchmarking insights. Synergy's workflow optimization speeds and simplifies transactions through digital automation, mutualizes risk and allows for better, more enlightened decision-making across organizations and functions. It also offers broad technology distribution that provides industry-wide connectivity to new technologies, reducing the cost of ownership for all. The Synergy Network has built a critical mass of data, participants and solutions with leading financial institutions and processes over a billion transactions every month. For more information, please visit or follow us on LinkedIn or X. Media Contactmarketing@ View original content to download multimedia: SOURCE AccessFintech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know
